Home | About Us | Contact Us | Register | Disease Awareness Productions | Subscribe to MDTV | Login
Since 1998... America's Leading Resource for Medical News • On The Air Nationwide • The Patient Advocate • MDTV Inc. is a Not for Profit Charity
MDTV | On The Air Nationwide.... On The Web & Mobile Digital TV Worldwide
Sunday, April 11, 2021
Channel:
Topic:
Advanced Search
search sponsored by


MDTV Select® Urologist, Carson Wong, MD, FRCSC, FACS, Assistant Professor and Director, Section of Endourologic, Laparoscopic and Minimally Invasive Surgery at OU Medical Center


home : ok: oklahoma city- kocb/kokh : prostate cancer channel- oklahoma city, ok
April 11, 2021

National Cancer Institute offers
Prostate Cancer: Questions and Answers

National Cancer Institute


1.         What is the prostate?

The prostate is a gland in the male reproductive system. The prostate makes and stores a component of semen and is located near the bladder and the rectum. The prostate surrounds part of the urethra, the tube that empties urine from the bladder. A healthy prostate is about the size of a walnut. If the prostate grows too large, the flow of urine can be slowed or stopped.

2.         What is prostate cancer?

Except for skin cancer, cancer of the prostate is the most common malignancy in American men. It is estimated that nearly 235,000 men in the United States will be diagnosed with prostate cancer in 2006 (1). In most men with prostate cancer, the disease grows very slowly. The majority of men with low-grade, early prostate cancer (confined to the gland) live a long time after their diagnosis. Even without treatment, many of these men will not die of the prostate cancer, but rather will live with it until they eventually die of some other, unrelated cause. Nevertheless, nearly 27,000 men will die of prostate cancer in 2006 (1).

3.         Who is at risk for prostate cancer?

All men are at risk. The most common risk factor is age. More than 70 percent of men diagnosed with prostate cancer each year are over the age of 65. African American men have a higher risk of prostate cancer than white men. Dramatic differences in the incidence of prostate cancer are also seen in different countries, and there is some evidence that a diet higher in fat, especially animal fat, may account for some of these differences. Genetic factors also appear to play a role, particularly for families in which the diagnosis is made in men under age 60. The risk of prostate cancer rises with the number of close relatives who have the disease.

4.         What are the symptoms of prostate cancer?

Prostate cancer often does not cause symptoms for many years. By the time symptoms occur, the disease may have spread beyond the prostate. When symptoms do occur, they may include:

·              Frequent urination, especially at night.

·              Inability to urinate

·              Trouble starting or holding back urination.

·              A weak or interrupted flow of urine.

·              Painful or burning urination.

·              Blood in the urine or semen.

·              Painful ejaculation.

·              Frequent pain in the lower back, hips, or upper thighs.

These can be symptoms of cancer, but more often they are symptoms of noncancerous conditions. It is important to check with a doctor.

5.         What other prostate conditions can cause symptoms like these?

As men get older, their prostate may grow bigger and block the flow of urine or interfere with sexual function. This common condition, called benign prostatic hyperplasia (BPH), is not cancer, but can cause many of the same symptoms as prostate cancer. Although BPH may not be a threat to life, it may require treatment with medicine or surgery to relieve symptoms. An infection or inflammation of the prostate, called prostatitis, may also cause many of the same symptoms as prostate cancer. Again, it is important to check with a doctor.

6.         Can prostate cancer be found before a man has symptoms?

Yes. Two tests can be used to detect prostate cancer in the absence of any symptoms. One is the digital rectal exam (DRE), in which a doctor feels the prostate through the rectum to find hard or lumpy areas. The other is a blood test used to detect a substance made by the prostate called prostate-specific antigen (PSA). Together, these tests can detect many "silent" prostate cancers that have not caused symptoms.

At present, however, it is not known whether routine screening saves lives. The benefits of screening and local therapy (surgery or radiation) remain unclear for many patients. Because of this uncertainty, the National Cancer Institute (NCI), a part of the National Institutes of Health, is currently supporting research to learn more about screening men for prostate cancer. Currently, researchers are conducting a large study to determine whether screening men using a blood test for PSA and a DRE can help reduce the death rate from this disease. They are also assessing the risks of screening. Full results from this study, the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial (PLCO), are expected by 2015.

7.         How reliable are the screening tests for prostate cancer?

Neither of the screening tests for prostate cancer is perfect. Most men with mildly elevated PSA levels do not have prostate cancer, and many men with prostate cancer have normal levels of PSA. Also, the DRE can miss many prostate cancers. The DRE and PSA test together are better than either test alone in detecting prostate cancer.

The NCI Early Detection Research Network (EDRN) has a Prostate Collaborative Group, which is applying a variety of strategies to find better ways to detect prostate cancer early.

8.         How is prostate cancer diagnosed?

The diagnosis of prostate cancer can be confirmed only by a biopsy. During a biopsy, a urologist (a doctor who specializes in diseases of urinary and sex organs in men, and urinary organs in women) removes tissue samples, usually with a needle. This is generally done in the doctor's office with local anesthesia. Then a pathologist (a doctor who identifies diseases by studying tissues under a microscope) checks for cancer cells.

Prostate cancer is described by both grade and stage.

·              Grade describes how closely the tumor resembles normal prostate tissue. Based on the microscopic appearance of tumor tissue, pathologists may describe it as low-, medium-, or high-grade cancer. One way of grading prostate cancer, called the Gleason system, uses scores of 2 to 10. Another system uses G1 through G4. In both systems, the higher the score, the higher the grade of the tumor. High-grade tumors generally grow more quickly and are more likely to spread than low-grade tumors.

·              Stage refers to the extent of the cancer. Early prostate cancer, stages I and II, is localized. It has not spread outside the gland. Stage III prostate cancer, often called locally advanced disease, extends outside the gland to the seminal vesicles. Stage IV means the cancer has spread to lymph nodes and/or to other tissues or organs.

9.         How is localized prostate cancer treated?

Three treatment options are generally accepted for men with localized prostate cancer: radical prostatectomy, radiation therapy, and surveillance (also called watchful waiting).

·              Radical prostatectomy is a surgical procedure to remove the entire prostate gland and nearby tissues. Sometimes lymph nodes in the pelvic area (the lower part of the abdomen, located between the hip bones) are also removed. Radical prostatectomy may be performed using a technique called nerve-sparing surgery that may prevent damage to the nerves needed for an erection.

·              Radiation therapy involves the delivery of radiation energy to the prostate. The energy is usually delivered in an outpatient setting using an external beam of radiation. The energy can also be delivered by implanting radioactive seeds in the prostate using a needle.

·              Surveillance, taking a wait-and-see approach, may be recommended for patients with early-stage prostate cancer, particularly those who are older or have other serious medical conditions. These patients have regular examinations. If there is evidence of cancer growth, active treatment may be recommended.

10.       How does a patient decide what is the best treatment option for localized prostate cancer?

Choosing a treatment option involves the patient, his family, and one or more doctors (MDTVNews.com NOTE- see location sections or the blue and white pages on this site). They will need to consider the grade and stage of the cancer, the man's age and health, and his values and feelings about the potential benefits and harm of each treatment option. Often it is useful to seek a second opinion, and patients may hear different opinions and recommendations. Because there are several reasonable options for most patients, the decision can be difficult. Patients should try to get as much information as possible and allow themselves enough time to make a decision. There is rarely a need to make a decision without taking time to discuss and understand the pros and cons of the various approaches.

11.       Where can a person find more information about prostate cancer and its treatment?

The NCI has several other resources that readers may find helpful, including the following:

·              The Prostate Cancer home page provides links to NCI resources about prevention, screening, treatment, clinical trials, and supportive care for this type of cancer. This page can be found on the NCI's Web site at http://www.cancer.gov/prostate/ on the Internet.

·              Prostate Cancer (PDQ®): Treatment includes information about prostate cancer treatment, including surgery, chemotherapy, radiation therapy, and hormone therapy. This summary of information from PDQ, the NCI's comprehensive cancer information database, is available on the Internet.

·              Treatment Choices for Men With Early-Stage Prostate Cancer describes the treatment choices available to men diagnosed with early-stage prostate cancer and examines the pros and cons of each treatment. This NCI fact sheet is available at on the Internet.

 

Selected References

1.         Ries LAG, Harkins D, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2003. Bethesda, MD: National Cancer Institute, 2006.

# # #



Related Links:
• Prostate Cancer (PDQ®):
• NCI fact sheet



User Login

Username:
Password:
Remember me
Login reminder

Subscribe to MDTV
MDTV for Associations
MDTV Select Medical Associations/ Societies

Get Your own webMDTV Channel Free
MDTV Channel Types
Select Doctor Directory Blue and White Pages
Pregnancy and Autoimmune Diseases
Pregnancy and Autoimmune Directory of Doctors
Senior Health Library
Health News Today... Click Here
Heart Health News
Medline on MDTV
MDTV on the Business of Beauty
Plastic Surgery Videos
FDA News Now
Food Safety Tips
Weight Loss News
2: Pregnancy and Autoimmune Diseases
2: Womens Health Network
Healthy Home Network TV
MDTV Channels- Portable

MDTV Select Broadcast Stations


Theodore Falk MD
Expertise: Allergies and Immunology




Ask an MDTV Select ExpertFor Doctors OnlyMDTV Contact InformationMDTV Broadcast StationsMDTV for AssociationsLife
For Top Doctors Only

MDTV Inc., A New Jersey 501c3 Charity • 800-985-MDTV (6388)

OnMarsMedia • Mars Corporate Center • 3 Mars Court • Boonton Township, NJ 07005